89bio Stock News

ETNB stock has remained depressed for a long time. Not even solid SHTG data could change that.

In June, 89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia (SHTG).  SVB Leerink views these resul

89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia (SHTG).  Hypertriglyceridemia is characterized b

SAN FRANCISCO, June 21, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the

89bio, Inc (NASDAQ: ETNB) was plunging almost 10% lower on Friday in sympathy with the general market, which saw the S&P 500 plummeting over 2%. In May, a number of analysts weighed in on 89bio follow

SAN FRANCISCO, May 03, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the

Gainers Imperial Petroleum Inc. (NASDAQ: IMPP ) jumped 63.1% to close at $0.80 on Tuesday after declining around 7% on Friday. Indonesia Energy Corporation Limited (NYSE: INDO ) shares surged 44.1% to close at $6.47 on Tuesday. Meritor, Inc. (NYSE: MTOR ) shares climbed 43.8% to settle at $35.47. Cummins Inc (NYSE: CMI ) agreed to acquire electric powertrain solutions provider Meritor for about $3.7 billion, including assumed debt and net of acquired cash. China Natural Resources, Inc. (NASDAQ: CHNR ) surged 27.4% to close at $0.7901. Paltalk, Inc. (NASDAQ: PALT ) rose 26.1% to close at $3.96. Ocugen, Inc. (NASDAQ: OCGN ) gained 22.3% to close at $4.23. The FDA has lifted its clinical hold on Ocugens investigational new drug application seeking approval to conduct testing of the COVID-19 vaccine Covaxin in the U.S. Arteris, Inc. (NASDAQ: AIP ) climbed 19% to close at $17.83. Arteris is expected release its financial results for the fourth quarter on Thursday, March 3, 2022. SeaChange International, Inc. (NYSE: SEAC ) rose 18.9% to settle at $1.26.

SAN FRANCISCO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will participate in a fireside chat and one-on-one investor meetings at the SVB Leerink 11 th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 12:00 PM ET.

SAN FRANCISCO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the

89bio, Inc. (NASDAQ:ETNB) has earned an average rating of Buy from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered []

Zacks Investment Research lowered shares of 89bio (NASDAQ:ETNB) from a hold rating to a sell rating in a research note published on Tuesday, Zacks.com reports. According to Zacks, 89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The companys lead []

89bio, Inc. (NASDAQ:ETNB) insider Ram Waisbourd sold 7,000 shares of 89bio stock in a transaction dated Tuesday, November 16th. The shares were sold at an average price of $16.49, for a total value of $115,430.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Ram []

89bio, Inc. (NASDAQ:ETNB) Stock analysts at Oppenheimer dropped their FY2021 EPS estimates for shares of 89bio in a research note issued on Monday, November 15th. Oppenheimer analyst J. Olson now forecasts that the company will post earnings per share of ($4.71) for the year, down from their prior estimate of ($4.05). Oppenheimer also issued []

Data from a new sub-analysis of the Phase 1b/2a study in NASH shows correlation between increased liver fat and spleen volume in patients with non-cirrhotic NASH Data from a new sub-analysis of the Ph